AZD2171

AZD2171

File:AZD2171.svg
Clinical data
Routes of administration	Oral
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- 7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C25H27FN4O3
Molar mass	450.5 g/mol

WikiDoc Resources for AZD2171
Articles
Most recent articles on AZD2171 Most cited articles on AZD2171 Review articles on AZD2171 Articles on AZD2171 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on AZD2171 Images of AZD2171 Photos of AZD2171 Podcasts & MP3s on AZD2171 Videos on AZD2171
Evidence Based Medicine
Cochrane Collaboration on AZD2171 Bandolier on AZD2171 TRIP on AZD2171
Clinical Trials
Ongoing Trials on AZD2171 at Clinical Trials.gov Trial results on AZD2171 Clinical Trials on AZD2171 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on AZD2171 NICE Guidance on AZD2171 NHS PRODIGY Guidance FDA on AZD2171 CDC on AZD2171
Books
Books on AZD2171
News
AZD2171 in the news Be alerted to news on AZD2171 News trends on AZD2171
Commentary
Blogs on AZD2171
Definitions
Definitions of AZD2171
Patient Resources / Community
Patient resources on AZD2171 Discussion groups on AZD2171 Patient Handouts on AZD2171 Directions to Hospitals Treating AZD2171 Risk calculators and risk factors for AZD2171
Healthcare Provider Resources
Symptoms of AZD2171 Causes & Risk Factors for AZD2171 Diagnostic studies for AZD2171 Treatment of AZD2171
Continuing Medical Education (CME)
CME Programs on AZD2171
International
AZD2171 en Espanol AZD2171 en Francais
Business
AZD2171 in the Marketplace Patents on AZD2171
Experimental / Informatics
List of terms related to AZD2171

Overview

AZD2171 (tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

Further reading

• Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

External links

• AZD2171—AstraZeneca Pipeline